LABU241108C171000
- 0.15
- 0.000.00%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
Nasdaq 100 Extends Record Levels Ahead Of Fed Meeting, Tesla Hits 26-Month Highs, Small Caps Stall: What's Driving Markets Thursday?
BMO Capital Maintains Outperform on Gilead Sciences, Raises Price Target to $102
Evercore ISI Group Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $170
Neurocrine Biosciences Unveils KINECT-HD Data Demonstrating Consistent Efficacy Of INGREZZA In Huntington's Disease Chorea Across 19 Subgroups, Showing Positive Impact On Emotional Health
Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday
Vaccinex Announces Signing Of Proprietary Project Agreements With Amgen, Merck, Chugai, Absci, Gigagen, Merus, Soleil, ThirdArc And Incyte To Employ Vaccinex's ActivMAb Technology
Sarepta Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results. Also, Cantor Fitzgerald Upgraded the Stock From Neutral to Overweight and Raided Its Price Target From $152 to $167.
Gilead Sciences Analyst Ratings
This McKesson Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Needham Reiterates Buy on Sarepta Therapeutics, Maintains $205 Price Target
Gilead Sciences Declares $0.77 Dividend
Gilead Sciences in Charts: Revenue From Major Products Rises Y/Y in Q3
Gilead Rises as It Raises 2024 Sales, Non-GAAP EPS Outlook
Gilead Sciences Raises FY24 Product Sales Guidance From $27.10B - $27.50B To $27.80B - $28.10B
Sarepta Therapeutics Q3 2024 Adj. EPS $0.62 Beats $(0.13) Estimate, Sales $467.172M Beat $409.297M Estimate.
Gilead Sciences Non-GAAP EPS of $2.02 Beats by $0.47, Revenue of $7.55B Beats by $550M
SA Asks: How Will the U.S. Election Results Impact Healthcare Stocks?
Jefferies Maintains Buy on Exact Sciences, Raises Price Target to $85
AbbVie Analyst Ratings
What the Options Market Tells Us About AbbVie